Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib and Fulvestrant in HR+/HER2+ Metastatic Breast Cancer
NCT04034589Phase 2Unknown
- Sponsor
- Sun Yat-sen Memorial Hospital
- Start
- Jul 2019
- Primary completion
- Jul 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pyrotinib in breast cancer, sponsored by Sun Yat-sen Memorial Hospital. Primary endpoint: Progression-Free Survival at 12 months. Status: unknown.
02
Drugs
pyrotinib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04034589.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04034589.